Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Other Events
On June19, 2017, Seattle Genetics, Inc. (the Company) issued a
press release announcing, among other things, that it is
discontinuing its phase 3 CASCADE clinical trial of vadastuximab
talirine in frontline older acute myeloid leukemia patients. The
Companys press release is attached as Exhibit 99.1 to this
current report and is incorporated by reference herein.
|Item9.01||Financial Statements and Exhibits.|
|99.1||Press Release of Seattle Genetics, Inc. dated June19, 2017|
About Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.